Triiodothyronine
Obesity
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Phase 3Dormant
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 59/ 100
Competitive context
361 Active assets in the Obesity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
vi-0521 VIVUS LLC | Phase 4 | BBB |
Phentermine Russell McCulloh, MD | Phase 4 | BBB |
Cagrilintide Novo Nordisk A/S | Phase 3 | BBB |
Survodutide Boehringer Ingelheim | Phase 3 | BBB |
Mazdutide China National Center for Cardiovascular Diseases | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Triiodothyronine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →